David Nierengarten Analyst Performance

Managing Director, Equity Research at Wedbush

David Nierengarten is a stock analyst at Wedbush, covering 48 publicly traded companies across a range of sectors. Over the past year, David Nierengarten has issued 28 stock ratings, including buy and hold recommendations. While full access to David Nierengarten's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Nierengarten's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 121 Last 10 Years
Buy Recommendations: 65.25% 77 Buy Ratings
Companies Covered: 48 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	65.3%	77 ratings
Hold	29.7%	35 ratings
Sell	5.1%	6 ratings

Out of 118 total stock ratings issued by David Nierengarten at Wedbush, the majority (65.3%) have been Buy recommendations, followed by 29.7% Hold and 5.1% Sell.

Best & Worst Calls

Best Call
0000.0%
TSRO
Mar 2016
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
DARE
Apr 2016
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	95.8% of companies on NASDAQ	46 companies
NYSE	4.2% of companies on NYSE	2 companies

David Nierengarten, an analyst at Wedbush, currently covers 48 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 43 companies	89.6%
	Miscellaneous 5 companies	10.4%

David Nierengarten of Wedbush specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 24 companies	50.0%
PHARMACEUTICAL PREPARATIONS 8 companies	16.7%
MED - DRUGS 5 companies	10.4%
Miscellaneous 4 companies	8.3%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 3 companies	6.3%
BIOTECHNOLOGY 2 companies	4.2%
SURGICAL & MEDICAL INSTRUMENTS 1 company	2.1%
HOLDING & OTHER INVESTMENT OFFICES 1 company	2.1%

About David Nierengarten

David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models. In addition, David has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor. David received his B.S. in Biochemistry from the University of Wisconsin-Madison, and Ph.D. in Molecular and Cell Biology from the University of California at Berkeley.

Time Frame

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
STTK Shattuck Labs	9/8/2025	Initiated Coverage	$1.55	$4.00	Outperform
NUVB Nuvation Bio	9/8/2025	Reiterated Rating	$3.88	$6.00	Outperform
NUVL Nuvalent	9/8/2025	Reiterated Rating	$80.89	$115.00	Outperform
XNCR Xencor	9/2/2025	Reiterated Rating	$8.55	$26.00	Outperform
TLX Telix Pharmaceuticals	8/28/2025	Reiterated Rating	$12.10	$22.00	Outperform
GBIO Generation Bio	8/13/2025	Downgrade	$4.05	$7.00	Neutral
XNCR Xencor	8/7/2025	Lower Price Target	$7.49	$26.00	Outperform
IMA ImageneBio	7/25/2025	Lower Price Target	$16.32	$23.00	Neutral
ARGX argenex	6/24/2025	Reiterated Rating	$550.14	$715.00	Outperform
CATX Perspective Therapeutics	6/23/2025	Reiterated Rating	$3.53	$11.00	Outperform
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
NUVB Nuvation Bio	6/11/2025	Reiterated Rating	$2.14	$5.00	Outperform
ARGX argenex	6/11/2025	Reiterated Rating	$575.46	$715.00	Outperform
TLX Telix Pharmaceuticals	6/5/2025	Initiated Coverage	$17.48	$22.00	Outperform
BPMC Blueprint Medicines	6/2/2025	Downgrade	$101.15	$129.00	Neutral
ITOS iTeos Therapeutics	5/28/2025	Downgrade	$10.43	$12.00	Neutral
NTLA Intellia Therapeutics	5/19/2025	Reiterated Rating	$9.09	$10.00	Neutral
NUVB Nuvation Bio	5/15/2025	Reiterated Rating	$2.24	$5.00	Outperform
BPMC Blueprint Medicines	4/16/2025	Reiterated Rating	$79.46	$128.00	Outperform
NVCR NovoCure	4/16/2025	Lower Price Target	$15.66	$27.00	Neutral
KNSA Kiniksa Pharmaceuticals International	4/16/2025	Reiterated Rating	$20.59	$34.00	Outperform
ARGX argenex	4/11/2025	Reiterated Rating	$577.38	$715.00	Outperform
IMNM Immunome	3/20/2025	Reiterated Rating	$8.64	$33.00	Outperform
STRO Sutro Biopharma	3/14/2025	Downgrade	$1.25	$2.00	Neutral
FATE Fate Therapeutics	3/6/2025	Reiterated Rating	$0.91	$5.00	Neutral
SWTX SpringWorks Therapeutics	2/10/2025	Reiterated Rating	$54.00	$77.00	Outperform
BCAX Bicara Therapeutics	2/6/2025	Initiated Coverage	$12.72	$31.00	Outperform
ANAB AnaptysBio	2/3/2025	Reiterated Rating	$17.27	$40.00	Outperform
BPMC Blueprint Medicines	1/13/2025	Reiterated Rating	$93.42	$124.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.